反应详情

Following the procedure in Example 1, step 6, 4-[3-(4-fluoro-phenoxy)-benzylidene]-piperidine hydrochloride (200 mg, 0.625 mmol, from Example 18, Step 3) and phenyl pyridin-3-ylcarbamate (147 mg, 0.688 mmol) were used to provide the title compound (238 mg). MS (APCI 10 V) AP+ 404.3, AP− 402.1; 1H NMR (400 MHz, CD3OD) δ ppm 2.43 (td, J=5.79, 1.10 Hz, 2H) 2.52 (td, J=5.89, 1.01 Hz, 2H) 3.51-3.55 (m, 2H) 3.60-3.66 (m, 2H) 6.40 (s, 1H) 6.78-6.84 (m, 2H) 6.95-6.98 (m, J=7.67, 1.53, 0.75, 0.75 Hz, 1H) 6.98-7.04 (m, 2H) 7.05-7.15 (m, 2H) 7.30 (t, J=7.77 Hz, 1H) 7.34 (ddd, J=8.41, 4.84, 0.76 Hz, 1H) 7.91 (ddd, J=8.38, 2.60, 1.45 Hz, 1H) 8.16 (dd, J=4.85, 1.46 Hz, 1H) 8.58 (dd, J=2.62, 0.67 Hz, 1H).